- $1.06bn
- $1.26bn
- $272.30m
Brief: Harrow Licenses Canadian Rights To Apotex For Five Branded Ophthalmic Pharmaceutical Products
Brief: Harrow Announces Availability Of Vevye
Brief: Private Capital Management Llc Reports 10.34% Passive Stake In Harrow Inc As Of Dec 31, 2023
Brief: Melt Pharmaceuticals Says Co Expects To Begin MELT-300 Phase 3 Program in Q1 2024
U.S. STOCKS ON THE MOVE-Gold miners, Big Tech, Talis Biomedical
U.S. STOCKS ON THE MOVE-US banks, Splunk, ReAlpha Tech
Harrow falls on downbeat Q3 revenue
U.S. STOCKS ON THE MOVE-Snap, Tesla, BioCardia
Harrow Health falls on downbeat Q3 revenue
Brief: Harrow Health, Inc. Changes Corporate Name To Harrow, Inc.
Harrow Health Inc reports results for the quarter ended in June - Earnings Summary
Brief: Harrow Health Q2 core EPS USD -0.02
Harrow Health Inc expected to post a loss of 4 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Bluebird bio, Panbela, Northern Trust
U.S. STOCKS ON THE MOVE-Constellation Brands, Baker Hughes, Hasbro
U.S. STOCKS ON THE MOVE-Meta Platforms, Tesla, US health insurers
Harrow Health falls on discounted public offering
Brief: Harrow Prices $60 Million Public Offering Of Common Stock
Harrow Health rises on separate deals for eye disease drugs, Q2 rev forecast